

## CORPORATE PROFILE

Knight Therapeutics Inc., founded in 2014 by Jonathan Ross Goodman (co-founder of Paladin Labs Inc.), is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and select international markets. In addition, Knight invests in or finances other life sciences companies with the goal of securing product distribution rights. Knight has acquired or in-licensed a portfolio of over 20 products that are marketed, under regulatory review or in various stages of development. Knight is headquartered in Montreal, Quebec, Canada and has over 45 employees.

## FINANCIAL RESULTS

In '000s of CAD except per share amounts

	Three Months Ended Mar 31, 2019	Fiscal Year Dec 31, 2018	Fiscal Year Dec 31, 2017
Revenue	2,956	12,500	8,634
Net Income	5,189	24,079	17,244
Cash and marketable securities	748,411	787,062	765,033
Per share <sup>1</sup>	5.24	5.51	5.36
Net Asset Value	1,032,551	1,030,032	991,208
Per share <sup>1</sup>	7.23	7.21	6.94

<sup>1</sup>Based on common shares outstanding as at March 31, 2019

## INVESTMENT HIGHLIGHTS

- Proven partner for the Canadian and select international markets
- Demonstrated ability to secure profitable licensing agreements
- Experienced and dynamic management team with proven track record of success
- Financial strength to execute its strategy

## ANALYST COVERAGE

### Bloom Burton & Co.

David Martin  
dmartin@bloomburton.com

### Mackie Research

Andre Uddin  
auidin@mackieresearch.com

### RBC Dominion Securities

Douglas Miehme  
douglas.miehme@research.rbccm.com

### Cormack Securities

Tania Gonsalves  
tgonsalves@cormack.com

### National Bank Financial

Endri Leno  
endri.leno@nbc.ca

### Raymond James

David Novack  
david.novack@raymondjames.com

### GMP Securities

Justin Keywood  
jkeywood@gmpsecurities.com

### Paradigm Capital

Rahul Sarugaser  
rsarugaser@paradigmcap.com

### TD Securities

Lennox Gibbs  
lennox.gibbs@tdsecurities.com

## MARKET FACTS

(As at May 8, 2019)

Symbol: **TSX: GUD**

Share Price: **\$7.50**

Shares Outstanding: **142.9 M**

Market Capitalization: **\$1.07 B**

## MANAGEMENT TEAM

### Jonathan Ross Goodman

CEO

### Samira Sakhia

President and CFO

### Amal Khouri

VP, Business Development

## BOARD OF DIRECTORS

### James Gale (Chairman)

### Jonathan Ross Goodman

### Samira Sakhia

### Robert Lande

### Sylvie Tandler

### Nancy Harrison

### Michael Tremblay

### Kevin Cameron

## INVESTOR CONTACT

Knight Therapeutics Inc.  
Samira Sakhia, President and CFO  
Tel: 514.678.8930  
Fax: 514.481.4116  
E-mail: [info@gudknight.com](mailto:info@gudknight.com)  
Website: [www.gud-knight.com](http://www.gud-knight.com)